Traws Pharma, Inc.
NASDAQTRAW, the small Nasdaq-listed pharma, has become one of the most expensive stocks to borrow in the US market. In one week, cost to borrow exploded from under 1.5% to 292% annualized — a rise of nearly 19,800%. The lending pool is now fully exhausted. Availability has collapsed to zero. Every share in the borrow market is already lent out. The…
TRAW short sellers face maximum squeeze pressure: utilization at 100%, cost to borrow explodes to 292% annualized.
Short interest % of float, cost to borrow, utilization, and put/call ratio for TRAW are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 15 May 2026
TRAW, the small Nasdaq-listed pharma, has become one of the most expensive stocks to borrow in the US market. In one week, cost to borrow exploded from under 1.5% to 292% annualized — a rise of nearly 19,800%. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRAW — free to start on ORTEX.
Sign up for free →Open TRAW on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live TRAW data →